[Cisplatin, adriamycin and mitomycin-C in advanced stomach cancer].
Eighteen patients with advanced gastric cancer were treated with cisplatin 80 mg/m2 d 1, doxorubicin 30 mg/m2 d 3 and mitomycin-C 12 mg/m2 d 3. One complete and 6 partial responses were observed in 17 evaluable patients (41%, confidence interval 17-65%). Median duration of response was 7 months; median survival was 8 months. One death due to toxicity was observed. This combination of 3 active drugs should not be recommended in cases of gastric cancers.
Louvet
C
C
GERCOD (groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs) hôpital St-Antoine, Paris, France.
de Gramont
A
A
Demuynck
B
B
Varette
C
C
Lagadec
B
B
Cady
J
J
Krulik
M
M
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin
Cisplatine, adriamycine et mitomycine-C dans le cancer de l'estomac avancé.